Regulatory Q&A Forum
Ask questions, share knowledge, and get help from the regulatory community
While sponsors often seek a direct figure for biocompatibility testing costs, isn't the more critical question about understanding the variables that drive the total investment? For example, how does ...
Given that a fixed price for biocompatibility testing is not feasible without a specific device and its materials, what is a comprehensive framework for how sponsors can strategically budget for and m...
When selecting a UK Responsible Person (UKRP) for placing a medical device on the Great Britain market, how can a non-UK manufacturer move beyond a basic compliance check and conduct a thorough due di...
For non-UK medical device manufacturers, appointing a UK Responsible Person (UKRP) is a mandatory step for placing devices on the Great Britain market. While a common question revolves around the annu...
When a medical device manufacturer based outside the European Union intends to place a product on the EU market, they must appoint an EU Authorised Representative (EUAR). This is a mandatory legal rol...
What are Class II Special Controls and how do they impact the 510(k) submission process for a medical device? In the U.S. FDA’s risk-based classification system, Class II devices are those with a mod...
When a medical device manufacturer without a physical presence in a key market like the European Union needs to appoint an Authorized Representative, evaluating the associated costs involves more than...
For non-EU companies processing the personal data of EU residents, appointing a GDPR Article 27 Representative is often a mandatory requirement. While the service appears straightforward, the costs ca...
As global standards like ISO 10993-1 evolve towards a 2026 horizon, how can manufacturers effectively pivot from a historical, checklist-driven biocompatibility testing model to a more integrated, ris...
With significant updates to international consensus standards for biological evaluation on the horizon, how should medical device manufacturers strategically vet and select a biocompatibility testing ...
For a non-UK based medical device manufacturer preparing for UK market access, selecting a UK Responsible Person (UKRP) is a critical compliance step. Beyond simply having a registered address in Grea...
For a non-UK medical device manufacturer planning for market access in 2026, what are the primary factors that influence the cost of engaging a UK Responsible Person (UKRP)? Beyond a simple flat fee, ...
With the European Union implementing significant updates to its cosmetics framework, including new substance restrictions and digital labeling initiatives slated for enforcement through 2026, how shou...
For non-EU manufacturers placing medical devices on the European market, the selection of an EU Authorized Representative (EUAR) is a critical compliance step under the Medical Device Regulation (MDR)...
For non-EU based medical device manufacturers, particularly those developing Software as a Medical Device (SaMD) or connected health products that process personal data of EU residents, selecting a Eu...
When a non-EU medical device or SaMD company processes the personal data of individuals in the European Union, appointing a GDPR Article 27 Representative is a mandatory compliance step. However, sele...
Under the EU Medical Device Regulation (MDR), the role of the Authorized Representative (AR) has evolved from a simple liaison to a legally liable partner. For a non-EU manufacturer of a device, such ...
As the UK medical device regulatory framework continues to evolve, with significant deadlines anticipated around 2026, non-UK manufacturers face the critical task of appointing a UK Responsible Person...
As the UK's regulatory landscape for medical devices evolves, manufacturers based outside the UK must appoint a UK Responsible Person (UKRP) to place devices on the Great Britain market. Beyond the ba...
When a non-EU cosmetics manufacturer plans to enter the European market, selecting a Responsible Person (RP) is a critical compliance step. Given the evolving regulatory landscape, how can a company m...